Alumis Secures Record-Breaking $259M Series C Financing for Precision Immunology Drug Development

1. Alumis, previously known as Esker Therapeutics, has closed a $259 million Series C financing round, marking the largest private biotech fundraise of 2024 so far.
2. This substantial funding follows Alumis' previous successful Series B round, where they raised $200 million in 2022.
3. The Series C funding will support Alumis' pipeline of oral therapies aimed at addressing various medical needs, particularly in the field of precision immunology.
4. Notable investors participating in the Series C include Foresite Capital, Samsara BioCapital, venBio Partners, Cormorant Asset Management, SR One, Lilly Asia Ventures, Nextech, Ally Bridge Group, HBM Healthcare Investments, Omega Funds, and Piper Heartland Healthcare, along with existing investors such as AyurMaya, Matrix Capital Management, and a U.S.-based healthcare-focused fund.
5. Alumis had previously changed its name from Esker Therapeutics to reflect their shift towards precision immunology in early 2022.